{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:09:20Z","timestamp":1790194160796,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hormone receptor (HR)\u2013positive breast cancer accounts for approximately 60% of all breast cancer cases, for which endocrine therapy represents the mainstay of treatment; however, the development of therapeutic resistance substantially limits its clinical efficacy. Extracellular adenosine 5\u2032-triphosphate (ATP) has been implicated as a key mediator of metastasis and chemotherapy resistance in multiple malignancies, including breast cancer, yet its role in endocrine resistance remains poorly defined. Here, we demonstrate that extracellular ATP upregulates glycogen phosphorylase L (PYGL) expression in ER-positive breast cancer cells following endocrine treatment, thereby promoting endocrine resistance. Mechanistically, extracellular ATP activates the P2Y12\u2013AhR signaling axis, leading to increased PYGL expression, enhanced glycolytic activity, and subsequent resistance to endocrine therapy. Moreover, elevated PYGL expression was strongly associated with reduced endocrine therapy sensitivity in breast cancer organoids and clinical tumor specimens. Collectively, these findings identify extracellular ATP\u2013driven PYGL activation as a critical mechanism underlying endocrine resistance and suggest that targeting this pathway may represent a promising strategy to improve endocrine therapy efficacy in breast cancer patients.<\/jats:p>","DOI":"10.1038\/s41419-026-08736-8","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:45:55Z","timestamp":1776087955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extracellular ATP promotes endocrine resistance in ER+ breast cancer through upregulation of PYGL"],"prefix":"10.1038","volume":"17","author":[{"given":"Yu-Qing","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7058-8274","authenticated-orcid":false,"given":"Liang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1593-4987","authenticated-orcid":false,"given":"Xin-Xia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"8736_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8736_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573\u201383.","journal-title":"Nat Rev Clin Oncol"},{"key":"8736_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535.","journal-title":"Int Immunopharmacol"},{"key":"8736_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(78)90053-3","volume":"1","author":"JS Patterson","year":"1978","unstructured":"Patterson JS, Baum M. Safety of tamoxifen. Lancet. 1978;1:105.","journal-title":"Lancet"},{"key":"8736_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020;37:496\u2013513.","journal-title":"Cancer Cell"},{"key":"8736_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.breast.2016.10.001","volume":"31","author":"F Cardoso","year":"2017","unstructured":"Cardoso F, Costa A, Senkus E, Aapro M, Andr\u00e9 F, Barrios CH, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017;31:244\u201359.","journal-title":"Breast"},{"key":"8736_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427\u201338.e6.","journal-title":"Cancer Cell"},{"key":"8736_CR8","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1038\/s41388-020-01402-z","volume":"39","author":"H Yang","year":"2020","unstructured":"Yang H, Geng YH, Wang P, Yang H, Zhou YT, Zhang HQ, et al. Extracellular ATP promotes breast cancer invasion and chemoresistance via SOX9 signaling. Oncogene. 2020;39:5795\u2013810.","journal-title":"Oncogene"},{"key":"8736_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301084","volume":"12","author":"J Yang","year":"2023","unstructured":"Yang J, Qu J, Teng X, Zhu W, Xu Y, Yang Y, et al. Tumor microenvironment-responsive hydrogel for direct extracellular ATP imaging-guided surgical resection with clear boundaries. Adv Health Mater. 2023;12:e2301084.","journal-title":"Adv Health Mater"},{"key":"8736_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/onc.2016.206","volume":"36","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2017;36:293\u2013303.","journal-title":"Oncogene"},{"key":"8736_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.canlet.2010.01.010","volume":"293","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Gong LH, Zhang HQ, Du Q, You JF, Tian XX, et al. Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression. Cancer Lett. 2010;293:189\u201397.","journal-title":"Cancer Lett"},{"key":"8736_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/cas.13273","volume":"108","author":"JL Zhang","year":"2017","unstructured":"Zhang JL, Liu Y, Yang H, Zhang HQ, Tian XX, Fang WG. ATP-P2Y2-beta-catenin axis promotes cell invasion in breast cancer cells. Cancer Sci. 2017;108:1318\u201327.","journal-title":"Cancer Sci"},{"key":"8736_CR13","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/cas.14086","volume":"110","author":"H Yang","year":"2019","unstructured":"Yang H, Geng YH, Wang P, Zhou YT, Yang H, Huo YF, et al. Extracellular ATP promotes breast cancer invasion and epithelial-mesenchymal transition via hypoxia-inducible factor 2alpha signaling. Cancer Sci. 2019;110:2456\u201370.","journal-title":"Cancer Sci"},{"key":"8736_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.04.043","volume":"430","author":"Y Liu","year":"2018","unstructured":"Liu Y, Geng YH, Yang H, Yang H, Zhou YT, Zhang HQ, et al. Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts. Cancer Lett. 2018;430:1\u201310.","journal-title":"Cancer Lett"},{"key":"8736_CR15","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/cas.15375","volume":"113","author":"YT Zhou","year":"2022","unstructured":"Zhou YT, Yu YQ, Yang H, Yang H, Huo YF, Huang Y, et al. Extracellular ATP promotes angiogenesis and adhesion of TNBC cells to endothelial cells via upregulation of CTGF. Cancer Sci. 2022;113:2457\u201371.","journal-title":"Cancer Sci"},{"key":"8736_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.canlet.2004.05.023","volume":"215","author":"L Chen","year":"2004","unstructured":"Chen L, He HY, Li HM, Zheng J, Heng WJ, You JF, et al. ERK1\/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett. 2004;215:239\u201347.","journal-title":"Cancer Lett"},{"key":"8736_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3892\/or.2015.3979","volume":"34","author":"J Xia","year":"2015","unstructured":"Xia J, Yu X, Tang L, Li G, He T. P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol Rep. 2015;34:103\u201310.","journal-title":"Oncol Rep"},{"key":"8736_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1086\/301790","volume":"62","author":"B Burwinkel","year":"1998","unstructured":"Burwinkel B, Bakker HD, Herschkovitz E, Moses SW, Shin YS, Kilimann MW. Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. Am J Hum Genet. 1998;62:785\u201391.","journal-title":"Am J Hum Genet"},{"key":"8736_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mam.2015.09.002","volume":"46","author":"L Agius","year":"2015","unstructured":"Agius L. Role of glycogen phosphorylase in liver glycogen metabolism. Mol Asp Med. 2015;46:34\u201345.","journal-title":"Mol Asp Med"},{"key":"8736_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cmet.2012.10.017","volume":"16","author":"E Favaro","year":"2012","unstructured":"Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C, et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab. 2012;16:751\u201364.","journal-title":"Cell Metab"},{"key":"8736_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05005-2","volume":"13","author":"CE Zois","year":"2022","unstructured":"Zois CE, Hendriks AM, Haider S, Pires E, Bridges E, Kalamida D, et al. Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation. Cell Death Dis. 2022;13:573.","journal-title":"Cell Death Dis"},{"key":"8736_CR22","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.1080\/21655979.2021.1973775","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Liu X, Liu X, Zhi Y. Long noncoding RNA KCNMB2-AS1 promotes the development of esophageal cancer by modulating the miR-3194-3p\/PYGL axis. Bioengineered. 2021;12:6687\u2013702.","journal-title":"Bioengineered"},{"key":"8736_CR23","doi-asserted-by":"publisher","first-page":"12985","DOI":"10.1080\/21655979.2022.2079304","volume":"13","author":"G Wang","year":"2022","unstructured":"Wang G, Tao X, Peng L. miR-155-5p regulates hypoxia-induced pulmonary artery smooth muscle cell function by targeting PYGL. Bioengineered. 2022;13:12985\u201397.","journal-title":"Bioengineered"},{"key":"8736_CR24","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.7150\/ijbs.76756","volume":"19","author":"Q Ji","year":"2023","unstructured":"Ji Q, Li H, Cai Z, Yuan X, Pu X, Huang Y, et al. PYGL-mediated glucose metabolism reprogramming promotes EMT phenotype and metastasis of pancreatic cancer. Int J Biol Sci. 2023;19:1894\u2013909.","journal-title":"Int J Biol Sci"},{"key":"8736_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13046-023-02734-w","volume":"42","author":"J Guan","year":"2023","unstructured":"Guan J, Xu X, Qiu G, He C, Lu X, Wang K, et al. Cellular hierarchy framework based on single-cell\/multi-patient sample sequencing reveals metabolic biomarker PYGL as a therapeutic target for HNSCC. J Exp Clin Cancer Res. 2023;42:162.","journal-title":"J Exp Clin Cancer Res"},{"key":"8736_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00018-019-03281-4","volume":"77","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wang Q, Wang Q, Cao J, Sun J, Zhu Z. Mechanisms of resistance to estrogen receptor modulators in ER+\/HER2- advanced breast cancer. Cell Mol Life Sci. 2020;77:559\u201372.","journal-title":"Cell Mol Life Sci"},{"key":"8736_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neo.2020.12.009","volume":"23","author":"F Marcucci","year":"2021","unstructured":"Marcucci F, Rumio C. Glycolysis-induced drug resistance in tumors-A response to danger signals? Neoplasia. 2021;23:234\u201345.","journal-title":"Neoplasia"},{"key":"8736_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15:1170\u20138.","journal-title":"Nat Med"},{"key":"8736_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nm1617","volume":"13","author":"M Idzko","year":"2007","unstructured":"Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 2007;13:913\u20139.","journal-title":"Nat Med"},{"key":"8736_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tips.2006.02.004","volume":"27","author":"N White","year":"2006","unstructured":"White N, Burnstock G. P2 receptors and cancer. Trends Pharm Sci. 2006;27:211\u20137.","journal-title":"Trends Pharm Sci"},{"key":"8736_CR31","doi-asserted-by":"publisher","first-page":"19137","DOI":"10.1074\/jbc.M113.540047","volume":"289","author":"R Xie","year":"2014","unstructured":"Xie R, Xu J, Wen G, Jin H, Liu X, Yang Y, et al. The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. J Biol Chem. 2014;289:19137\u201349.","journal-title":"J Biol Chem"},{"key":"8736_CR32","first-page":"41","volume":"11","author":"CQ Hu","year":"2024","unstructured":"Hu CQ, Hou T, Xiang R, Li X, Li J, Wang TT, et al. PANX1-mediated ATP release confers FAM3A\u2019s suppression effects on hepatic gluconeogenesis and lipogenesis. Mil Med Res. 2024;11:41.","journal-title":"Mil Med Res"},{"key":"8736_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11302-019-09676-z","volume":"15","author":"Z Tang","year":"2019","unstructured":"Tang Z, Ye W, Chen H, Kuang X, Guo J, Xiang M, et al. Role of purines in regulation of metabolic reprogramming. Purinerg Signal. 2019;15:423\u201338.","journal-title":"Purinerg Signal"},{"key":"8736_CR34","first-page":"628","volume":"42","author":"C Ma","year":"2019","unstructured":"Ma C, Zu X, Liu K, Bode AM, Dong Z, Liu Z, et al. Knockdown of Pyruvate Kinase M inhibits cell growth and migration by reducing NF-kB activity in triple-negative breast cancer cells. Mol Cells. 2019;42:628\u201336.","journal-title":"Mol Cells"},{"key":"8736_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cell.2014.04.046","volume":"158","author":"G Sutendra","year":"2014","unstructured":"Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell. 2014;158:84\u201397.","journal-title":"Cell"},{"key":"8736_CR36","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.semcancer.2022.10.009","volume":"86","author":"J Lin","year":"2022","unstructured":"Lin J, Liu G, Chen L, Kwok HF, Lin Y. Targeting lactate-related cell cycle activities for cancer therapy. Semin Cancer Biol. 2022;86:1231\u201343.","journal-title":"Semin Cancer Biol"},{"key":"8736_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4103\/0250-474X.70472","volume":"72","author":"MP Suthar","year":"2010","unstructured":"Suthar MP, Patel MM. Optimization of luminescent assay for screening of cyclin-dependent kinase 2 inhibitors. Indian J Pharm Sci. 2010;72:290\u20134.","journal-title":"Indian J Pharm Sci"},{"key":"8736_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41422-020-0372-z","volume":"31","author":"J Liu","year":"2021","unstructured":"Liu J, Peng Y, Shi L, Wan L, Inuzuka H, Long J, et al. Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Res. 2021;31:80\u201393.","journal-title":"Cell Res"},{"key":"8736_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/toxsci\/kfs253","volume":"130","author":"R Lo","year":"2012","unstructured":"Lo R, Matthews J. High-resolution genome-wide mapping of AHR and ARNT binding sites by ChIP-Seq. Toxicol Sci. 2012;130:349\u201361.","journal-title":"Toxicol Sci"},{"key":"8736_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52001-2","volume":"9","author":"P Dornbos","year":"2019","unstructured":"Dornbos P, Jurgelewicz A, Fader KA, Williams K, Zacharewski TR, LaPres JJ. Characterizing the role of HMG-CoA Reductase in aryl hydrocarbon receptor-mediated liver injury in C57BL\/6 Mice. Sci Rep. 2019;9:15828.","journal-title":"Sci Rep"},{"key":"8736_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jare.2018.11.006","volume":"16","author":"HT Mohamed","year":"2019","unstructured":"Mohamed HT, Gadalla R, El-Husseiny N, Hassan H, Wang Z, Ibrahim SA, et al. Inflammatory breast cancer: Activation of the aryl hydrocarbon receptor and its target CYP1B1 correlates closely with Wnt5a\/b-beta-catenin signalling, the stem cell phenotype and disease progression. J Adv Res. 2019;16:75\u201386.","journal-title":"J Adv Res"},{"key":"8736_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2017.12.003","volume":"185","author":"AC Roman","year":"2018","unstructured":"Roman AC, Carvajal-Gonzalez JM, Merino JM, Mulero-Navarro S, Fernandez-Salguero PM. The aryl hydrocarbon receptor in the crossroad of signalling networks with therapeutic value. Pharm Ther. 2018;185:50\u201363.","journal-title":"Pharm Ther"},{"key":"8736_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2016.00001","volume":"4","author":"C Rabouille","year":"2016","unstructured":"Rabouille C, Linstedt AD. GRASP: a multitasking tether. Front Cell Dev Biol. 2016;4:1.","journal-title":"Front Cell Dev Biol"},{"key":"8736_CR44","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.apsb.2021.07.008","volume":"12","author":"J Shi","year":"2022","unstructured":"Shi J, Ju R, Gao H, Huang Y, Guo L, Zhang D. Targeting glutamine utilization to block metabolic adaptation of tumor cells under the stress of carboxyamidotriazole-induced nutrients unavailability. Acta Pharm Sin B. 2022;12:759\u201373.","journal-title":"Acta Pharm Sin B"},{"key":"8736_CR45","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.121.053960","volume":"144","author":"LY Lee","year":"2021","unstructured":"Lee LY, Oldham WM, He H, Wang R, Mulhern R, Handy DE, et al. Interferon-gamma impairs human coronary artery endothelial glucose metabolism by tryptophan catabolism and activates fatty acid oxidation. Circulation. 2021;144:1612\u201328.","journal-title":"Circulation"},{"key":"8736_CR46","doi-asserted-by":"crossref","unstructured":"Zhou N, Chen J, Ling Z, Zhang C, Zhou Y, Wang D, et al. Aryl hydrocarbon receptor sulfenylation promotes glycogenolysis and rescues cancer chemoresistance. J Clin Invest. 2023;133.","DOI":"10.1172\/JCI170753"},{"key":"8736_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1580-x","volume":"16","author":"Q Han","year":"2018","unstructured":"Han Q, Ma Y, Wang H, Dai Y, Chen C, Liu Y, et al. Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis. J Transl Med. 2018;16:201.","journal-title":"J Transl Med"},{"key":"8736_CR48","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/eji.202149481","volume":"52","author":"R Borella","year":"2022","unstructured":"Borella R, De Biasi S, Paolini A, Boraldi F, Lo Tartaro D, Mattioli M, et al. Metabolic reprograming shapes neutrophil functions in severe COVID-19. Eur J Immunol. 2022;52:484\u2013502.","journal-title":"Eur J Immunol"},{"key":"8736_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11302-013-9398-8","volume":"10","author":"G Burnstock","year":"2014","unstructured":"Burnstock G, Vaughn B, Robson SC. Purinergic signalling in the liver in health and disease. Purinerg Signal. 2014;10:51\u201370.","journal-title":"Purinerg Signal"},{"key":"8736_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ijc.28947","volume":"136","author":"S Gebremeskel","year":"2015","unstructured":"Gebremeskel S, LeVatte T, Liwski RS, Johnston B, Bezuhly M. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015;136:234\u201340.","journal-title":"Int J Cancer"},{"key":"8736_CR51","doi-asserted-by":"crossref","unstructured":"Elaskalani O, Falasca M, Moran N, Berndt MC, Metharom P. The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance. Cancers. 2017;9.","DOI":"10.3390\/cancers9100142"},{"key":"8736_CR52","doi-asserted-by":"crossref","unstructured":"Elaskalani O, Domenichini A, Abdol Razak NB, E Dye D, Falasca M, Metharom P. Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells. Cancers. 2020;12.","DOI":"10.3390\/cancers12010250"},{"key":"8736_CR53","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1016\/j.cell.2021.10.001","volume":"184","author":"Q Liu","year":"2021","unstructured":"Liu Q, Li J, Zhang W, Xiao C, Zhang S, Nian C, et al. Glycogen accumulation and phase separation drives liver tumor initiation. Cell. 2021;184:5559\u201376.e19.","journal-title":"Cell"},{"key":"8736_CR54","doi-asserted-by":"publisher","first-page":"4270s","DOI":"10.1158\/1078-0432.CCR-040020","volume":"10","author":"GI Shapiro","year":"2004","unstructured":"Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004;10:4270s\u20135s.","journal-title":"Clin Cancer Res"},{"key":"8736_CR55","doi-asserted-by":"publisher","first-page":"34566","DOI":"10.1074\/jbc.M004485200","volume":"275","author":"NG Oikonomakos","year":"2000","unstructured":"Oikonomakos NG, Schnier JB, Zographos SE, Skamnaki VT, Tsitsanou KE, Johnson LN. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J Biol Chem. 2000;275:34566\u201373.","journal-title":"J Biol Chem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08736-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08736-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08736-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:04:33Z","timestamp":1779167073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08736-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8736"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08736-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The use of postoperative tumor specimens and associated clinical data in this retrospective study was approved by the Peking University Biomedical Ethics Committee (Approval No. PUIRB-YS2025025). Informed consent was waived for the use of de-identified samples. All animal procedures were conducted in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee of Peking University (Approval No. BCAA0306).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors understand and agree with the content of the paper and agree to be listed as co-authors of the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"476"}}